Praveen Kumar Gaur

Dr. Praveen Kumar Gaur


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 May 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
SMShikha Mishra
Shikha Mishra
VAVidhu Aeri
Vidhu Aeri
PGPraveen Kumar Gaur
Praveen Kumar Gaur
SJSanjay M. Jachak
Sanjay M. Jachak
Boerhavia diffusa(BD) is a plant ofrasayanacategory as per ayurvedic claims. It is reported to possess antiaging, disease prevention, and life strengthening activities which hold enormous influence in disease burden and affordability/availability of healthcare in the world.Objective.This paper has been compiled to comment on the studies reported for BD to highlight its chemical and therapeutic potential along with its ethnopharmacological considerations.Methods.In the present paper, a detailed account of chemical constituents and pharmacological activities has been presented. All the findings were correlated with modern pharmacological activities to appraise the value of BD.Results.Chemical analysis of BD gives a wide variety of chemical constituents, namely, rotenoids, flavonoids, xanthones, purine nucleoside, lignans, and steroids. Various ethnopharmacological reports emphasize its role in disorders of reproductive system, gastrointestinal system, respiratory system, urinary system, hepatic system/jaundice, cardiovascular system, and cancer.Conclusions.The studies on the therapeutic activities of BD range from studies on crude extracts to isolated compounds; however some of the studies require sophistication and validated results. BD is a plant of enormous importance in the purview of its chemical and therapeutic properties.

21 May 2014 in BioMed Research International
Verified
Journal Article
Open access
PDF file
PGPraveen Kumar Gaur
Praveen Kumar Gaur
SMShikha Mishra
Shikha Mishra
MBMeenakshi Bajpai
Meenakshi Bajpai
AMAnushika Mishra
Anushika Mishra
Solid lipid nanoparticle is an efficient lipid based drug delivery system which can enhance the bioavailability of poorly water soluble drugs. Efavirenz is a highly lipophilic drug from nonnucleoside inhibitor category for treatment of HIV. Present work illustrates development of an SLN formulation for Efavirenz with increased bioavailability. At first, suitable lipid component and surfactant were chosen. SLNs were prepared and analyzed for physical parameters, stability, and pharmacokinetic profile. Efavirenz loaded SLNs were formulated using Glyceryl monostearate as main lipid and Tween 80 as surfactant. ESLN-3 has shown mean particle size of124.5±3.2nm with a PDI value of 0.234, negative zeta potential, and 86% drug entrapment.In vitrodrug release study has shown 60.6–98.22% drug release in 24 h by various SLN formulations. Optimized SLNs have shown good stability at 40°C±2°C and75±5% relative humidity (RH) for 180 days. ESLN-3 exhibited 5.32-fold increase in peak plasma concentration (Cmax⁡) and 10.98-fold increase in AUC in comparison to Efavirenz suspension (ES).

3 November 2017 in Artificial Cells, Nanomedicine, and Biotechnology
Verified
Journal Article
Closed access
MYMohd Yasir
Mohd Yasir
USUdai Vir Singh Sara
Udai Vir Singh Sara
ICIti Chauhan
Iti Chauhan
PGPraveen Kumar Gaur
Praveen Kumar Gaur
ASAlok Pratap Singh
Alok Pratap Singh
AMAmeeduzzafar
Ameeduzzafar
This study was aimed at preparing and characterizing solid lipid nanoparticles (SLNs) of donepezil (DPL) for delivery to brain via nasal route. SLNs were prepared by solvent emulsification diffusion technique using glyceryl monostearate (GMS) as lipid and blend of tween 80 and poloxamer 188 (1:1) as surfactant. Box–Behnken design was applied for optimization by using drug to lipid ratio, surfactant concentration and stirring time as dependent variables and their effect were observed on particles size, entrapment efficiency and drug loading. Optimized formulation was evaluated for particle size, zeta potential, entrapment efficiency, drug loading, morphological analysis, crystallinity, in vitro drug release, in vivo (biodistribution, pharmacokinetic and Gama scintigraphy) studies. For optimized formulation (OD3), value of particle size, zeta potential, percent in vitro release, entrapment efficiency and drug loading was found to be 121.0 nm, –24.1 mV, 89.35%, 67.95% and 12.15%, respectively. Pharmacokinetic and biodistribution studies were performed on albino Wistar rats and value of AUC0–∞ in brain for DPL-SLNs i.n. was found to be nearly 2.61 times higher than that of DPL-Sol i.v., whereas 2.26 times superior than DPL-Sol administered intranasally. The scintigraphy images were taken in rabbit and result revealed the localization of drug in brain.

1 December 2014 in Journal of Food and Drug Analysis
Verified
Journal Article
Open access
PGPraveen Kumar Gaur
Praveen Kumar Gaur
SMShikha Mishra
Shikha Mishra
MBMeenakshi Bajpai
Meenakshi Bajpai
The aim of this work was to design a controlled-release drug-delivery system for the angiotensin-II receptor antagonist drug telmisartan. Telmisartan was encapsulated with different EUDRAGIT polymers by an emulsion solvent evaporation technique and the physicochemical properties of the formulations were characterized. Using a solvent evaporation method, white spherical microspheres with particle sizes of 629.9-792.1 μm were produced. The in vitro drug release was studied in three different pH media (pH 1.2 for 2 hours, pH 6.8 for 4 hours, and pH 7.4 for 18 hours). The formulations were then evaluated for their pharmacokinetic parameters. The entrapment efficiency of these microspheres was between 58.6% and 90.56%. The obtained microspheres showed good flow properties, which were evaluated in terms of angle of repose (15.29-26.32), bulk and tapped densities (0.37-0.53 and 0.43-0.64, respectively), Carr indices and Hausner ratio (12.94-19.14% and 1.14-1.23, respectively). No drug release was observed in the simulated gastric medium up to 2 hours; however, a change in pH from 1.2 to 6.8 increased the drug release. At pH 7.4, formulations with EUDRAGIT RS 100 showed a steady drug release. The microsphere formulation TMRS-3 (i.e., microspheres containing 2-mg telmisartan) gave the highest Cmax value (6.8641 μg/mL) at 6 hours, which was three times higher than Cmax for telmisartan oral suspension (TOS). Correspondingly, the area under the curve for TMRS-3 was 8.5 times higher than TOS. Particle size and drug release depended on the nature and content of polymer used. The drug release mechanism of the TMRS-3 formulation can be explained using the Higuchi model. The controlled release of drug from TMRS-3 also provides for higher plasma drug content and improved bioavailability.

1 October 2017 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
NLNiharika Lal
Niharika Lal
JDJuhi Dubey
Juhi Dubey
PGPraveen Kumar Gaur
Praveen Kumar Gaur
NVNavneet Verma
Navneet Verma
AVAnurag Verma
Anurag Verma

1 September 2013 in Drug Invention Today
Verified
Journal Article
Closed access
RKRabee Kumar
Rabee Kumar
MYMohd Yasir
Mohd Yasir
SSShubhini A Saraf
Shubhini A Saraf
PGPraveen Kumar Gaur
Praveen Kumar Gaur
YKYatendra Kumar
Yatendra Kumar
ASAlok Pratap Singh
Alok Pratap Singh